Posted on

pot for pets today show

Here are the basics of what you need to know about CBD and health.

“I do believe that cannabidiol has potential, absolutely,” Dr. Yasmin Hurd, a neuroscientist at Mount Sinai Hospital in New York City, told TODAY. Hurd’s research suggests CBD can may have positive effects on opioid addicts.

CBD is everywhere lately — in skin care, coffee and even pet treats. But is it really all it’s hyped up to be?

Arthritis Foundation offers guidelines for CBD use

CBD is the abbreviation for cannabidiol, one of the many cannabinoids, or chemical compounds, found in marijuana and hemp.

Advocates say CBD, or cannabidiol, which comes from hemp and marijuana, can help with anxiety, pain relief and provide a slew of other benefits. And while many experts agree that CBD has potential, there are still a lot of unknowns.

The FDA has tested various products and found that many didn’t have the amount of CBD they had advertised, and has often sent warning letters to companies that make unfounded health claims.

You’re probably already familiar with tetrahydrocannabinol, or THC, which is another compound found in the cannabis plant and its main psychoactive component. But unlike THC, CBD is not psychoactive. In other words, it’s not what gets you stoned. It’s also different from medical marijuana, which has been shown to reduce pain.

The new rules proposed by the DEA last month were the result of an opinion written by lawyers in the DOJ’s Office of Legal Counsel in June 2018, while Sessions was still attorney general. The opinion concluded that the Single Convention treaty required the DEA to “monopolize” the exchange of all legal marijuana for research. The existing set-up — letting the University of Mississippi grow and ship marijuana — didn’t satisfy the Single Convention treaty, the memo concluded, and the DEA needed a new framework in which the agency takes control of the cannabis before distributing it to scientists.

However, the DEA still classifies marijuana as a Schedule I drug — a restrictive category reserved for substances believed to have no medical value and be susceptible to abuse. The DEA has repeatedly said it won’t support reclassifying marijuana because there aren’t well-controlled studies or scientific evidence approved by the Food and Drug Administration to show medical benefits. Yet scientists say that if evidence of those benefits is ever going to exist, they need to put real-world weed — not what’s made available from the University of Mississippi — through these studies.

Jeff Sessions pumps the brakes

The proposed regulations, the spokesman added, “could permit a greater range of product available for scientific research.”

But she was not happy with the weed she received.

This sets up a paradox, in which practically no one can show through an FDA-approved clinical trial that the cannabis products on the market are safe or beneficial because researchers can’t legally study them.